Nanoparticle-based liver-targeting therapy
AssigneeMidatech Limited
InventorsTom Coulter, Philip Williams
Life of this patent
Estimating the term…
Abstract
The present invention provides a nanoparticle comprising: a core comprising a metal and/or a semiconductor; and a plurality of ligands covalently linked to the core, wherein said ligands comprise: at least one liver-targeting ligand, such as C2-alpha galactose; at least one payload ligand comprising a bioactive agent, such as maytansinoid DM1; and at least one dilution ligand comprising a poly(ethyleneglycol) (PEG) moiety, such as PEG COOH. Also provided are pharmaceutical compositions comprising the nanoparticle, and uses of the nanoparticle in methods of treatment of liver disorders, including liver cancers such as hepatocellular carcinoma (HCC).
Claims21
A nanoparticle comprising:
- a core comprising a metal and/or a semiconductor;
- and
- a plurality of ligands covalently linked to the core, wherein said ligands comprise:
- (i) at least one galactose ligand;
- (ii) at least one maytansinoid DM1 ligand;
- and
- (iii) at least one dilution ligand comprising a poly or oligo ethylene glycol chain having a carboxylic acid end group.
A nanoparticle having the following structure:
Dependencies are inferred from the claim text.